The biopharmaceutical landscape stands at the cusp of a transformative era, with artificial intelligence (AI) leading the charge. For gene therapy developers, every key milestone significantly ...

ElevateBio will leverage artificial intelligence to expand and accelerate CRISPR discovery, design, and drug development for thousands of complex ...

company specialising in multimodal generative AI models, to advance its Parkinson’s disease gene therapy programme. Hologen has committed up to $430m in funding to support the development and ...

The startup will also use its generative AI technology to optimize manufacturing of the gene therapy, leveraging data that MeiraGTx has amassed over the course of nearly a decade developing its ...

The joint venture with generative AI firm Hologen hands MeiraGTx $200 million up front as well as other financial perks — a “transformative” deal, according to the company’s CEO.

Traditional methods for identifying therapeutic gene targets, crucial for personalized medicine, are expensive and time-consuming. While artificial intelligence (AI), particularly deep learning ...